Alprazolam: History

“[The public often] underestimate the extent to which certain disorders affect the general populace. When you treat them, it can make a tremendous amount of difference in their lives.” (David Sheehan, first discovered ’s efficacy in treating .[3])

was first synthesized by Upjohn (now a part of ). Its patent (#3,987,052)[4] was filed on October 29, 1969, granted on October 19, 1976 and expired in September 1993. It was released in 1981.[5][6] The first indication for which was approved was . Upjohn took this direction at the behest of a young David Sheehan. Sheehan’s suggestion was to use the confusion DSM-III created in the classification of (a distinction had just been made in DSM-III between (GAD) and ). was, at that point, perceived to be rare and treatable only with tricyclic ; were thought to be ineffective. However, from his , Sheehan knew to be both widespread among the populace and well responding to . He suggested to Upjohn that marketing for will both cover new diagnostic territory and stress the unique of this drug. Sheehan describes that the first group of patients treated by was so impressed by its action that they knew outright—this drug was going to be a hit. A few of the patients pooled their money and bought the Upjohn’s stock. Several months later, when was approved by the FDA, they sold out and made a profit.

Related posts

Comments

Leave a Reply